Raymond James downgraded 89bio (ETNB) to Market Perform from Outperform without a price target after the company entered into a merger agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash and an aggregate of $6 per share for three non-tradeable contingent value rights. While the deal is under Raymond James’ previous $50 target, it is a positive development, the analyst tells investors in a research note. The firm estimates the deal could close by the end of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB:
- 89bio downgraded to Neutral from Buy at H.C. Wainwright
- 89bio downgraded to Peer Perform from Outperform at Wolfe Research
- Nvidia to invest $5B in Intel, ABC pulls ‘Jimmy Kimmel Live!’: Morning Buzz
- Video: Intel powered up by Nvidia investment
- Morning Movers: Intel jumps following $5B investment from Nvidia